Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Lagerbericht

Marktkapitalisierung: US$17.8b

Neurocrine Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Neurocrine Biosciences wird ein jährliches Gewinn- und Umsatzwachstum von 24.2% bzw. 12% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 22.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 20.9% betragen.

Wichtige Informationen

24.2%

Wachstumsrate der Gewinne

22.61%

EPS-Wachstumsrate

Biotechs Gewinnwachstum25.3%
Wachstumsrate der Einnahmen12.0%
Zukünftige Eigenkapitalrendite20.95%
Analystenabdeckung

Good

Zuletzt aktualisiert07 Jul 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Analyseartikel • May 08

Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next

Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...

Recent updates

Narrativ-Update • Jul 08

NBIX: Sector Dependence And Product Uptake Uncertainty Will Pressure Forward Returns

Analysts have raised the Neurocrine Biosciences price target by about $8 to $151.68, citing updated models that reflect slightly higher projected revenue growth, profit margins, and a modestly higher future P/E multiple, supported by recent positive research commentary on Ingrezza, Crenessity, Vykat XR, and the broader biotech sector. Analyst Commentary Recent research on Neurocrine Biosciences points to generally constructive sentiment, with several firms lifting price targets and highlighting drivers such as Ingrezza expectations, the addition of Vykat XR, and the runway for key endocrine and neurology assets.
Seeking Alpha • Jul 02

Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno

Summary Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts. Patent protection through 2038 for Ingrezza and solid balance sheet support long-term growth, with pipeline approvals offering further upside potential. Read the full article on Seeking Alpha
Narrativ-Update • Jun 24

NBIX: Future Upside Will Rely On Expanding Rare Disease Franchise

Analysts have nudged their price target for Neurocrine Biosciences higher to $243.06 from $241.76, citing updated views on revenue growth, profit margins, and future P/E expectations following recent coverage initiations and the addition of Soleno Therapeutics' Vykat XR to the portfolio. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a generally constructive tone, with several firms updating views on the stock following the completion of the Soleno Therapeutics acquisition and fresh coverage initiations.
Analyseartikel • Jun 19

Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data

Neurocrine Biosciences (NBIX) is in focus after new CRENESSITY data at ENDO 2026 highlighted hormone normalization in classic CAH due to 11ß hydroxylase deficiency, alongside two-year cardiometabolic and bone health outcomes in adults. See our latest analysis for Neurocrine Biosciences. At a share price of $158.29, Neurocrine Biosciences has given investors a 23.97% 90 day share price return and a 25.08% 1 year total shareholder return, pointing to momentum that has built alongside ENDO 2026...
Narrativ-Update • Jun 09

NBIX: Future Upside Will Depend On Rare Disease Portfolio Execution

Analysts have lifted the fair value estimate for Neurocrine Biosciences by about $6 to $192.88, reflecting updated views on revenue growth, profitability and valuation after the Soleno acquisition, along with recent Street research highlighting a long runway for key drugs and additional contributions from Vykat XR. Analyst Commentary Recent Street research around Neurocrine Biosciences has been broadly constructive, with several firms updating models after the Soleno acquisition and new readthroughs on key products.
Narrativ-Update • May 26

NBIX: Pipeline Execution And Integration Risks Will Shape Balanced Future Returns

Analysts lifted their fair value target for Neurocrine Biosciences by about $3 to $144, citing updated assumptions for revenue growth of 14.83%, a profit margin of 18.43%, and a recalibrated future P/E of 21.28x that reflects confidence in the long runway of its key approved drugs and potential contributions from Crenessity and osavampator. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a mix of optimism around the company’s approved therapies and emerging pipeline, alongside selective caution on execution and valuation.
Analyseartikel • May 08

Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next

Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...
Narrativ-Update • May 07

NBIX: Future Upside Will Depend On Execution Across Two Core Franchises

The updated analyst price target for Neurocrine Biosciences moves to $241.76 from $203.91, with analysts pointing to higher modeled revenue growth and slightly richer future P/E assumptions, partly balanced by a modestly lower profit margin outlook and a small change in the discount rate. Analyst Commentary Recent Street research on Neurocrine Biosciences shows a cluster of price target changes and fresh coverage that tilt bullish overall, even with a few modest trims.
Narrativ-Update • Apr 21

NBIX: Future Upside Will Hinge On Tardive Dyskinesia Franchise Execution

The updated analyst price target for Neurocrine Biosciences increases to $186.45 from $178.04. Analysts attribute the change to more supportive long-term earnings expectations and higher assumed future P/E multiples, even as they refine revenue growth and margin assumptions.
Narrativ-Update • Apr 07

NBIX: Mixed 2026 Guidance And Policy Risks Will Shape Future Returns

Analysts have made a small upward adjustment to the fair value estimate for Neurocrine Biosciences to about $140.54, reflecting updated price targets that weigh mixed revisions across the Street against generally constructive views on Ingrezza and Crenessity. Analyst Commentary Street research around Neurocrine Biosciences has been active, with a mix of supportive views on key assets like Ingrezza and Crenessity and a series of price target tweaks that pull in different directions.
Narrativ-Update • Mar 24

NBIX: Future Upside Will Depend On Crenessity Adoption And Pipeline Progress

Analysts have trimmed the blended price target for Neurocrine Biosciences slightly to about $178, reflecting modest tweaks to growth, discount rate and P/E assumptions, while incorporating mixed but generally constructive views on Ingrezza and Crenessity uptake from recent research updates. Analyst Commentary Street research on Neurocrine Biosciences has been active, with several firms adjusting price targets and models around recent earnings, updated guidance and new information on Ingrezza and Crenessity.
Narrativ-Update • Mar 09

NBIX: 2026 Guidance Execution And CAH Competition Will Shape Future Returns

Analysts have kept the fair value estimate for Neurocrine Biosciences steady at $140, while revising their models slightly to reflect updated revenue growth, margins, and P/E assumptions following recent earnings, guidance, and a mix of modest price target cuts and a fresh $160 Outperform initiation. Analyst Commentary Across recent research, you are seeing a mix of optimism around the pipeline and commercial assets along with a cluster of more cautious valuation resets.
Narrativ-Update • Feb 23

NBIX: Execution On 2026 Guidance And Competitive CAH Data Will Shape Outlook

Neurocrine Biosciences' updated analyst price target of $140.00, down from $169.00, reflects refreshed models after Q4 results and 2026 guidance, with analysts still pointing to Ingrezza and Crenessity as key drivers in their long term assumptions despite recent target trims across the Street. Analyst Commentary Street research around Neurocrine Biosciences has turned more mixed, with several bearish analysts trimming price targets following Q4 results and updated 2026 guidance, while a few others have made only modest upward adjustments.
Narrativ-Update • Feb 09

NBIX: Future Returns Will Hinge On Crenessity Execution And Pipeline Delivery

Analysts made a modest trim to their Neurocrine Biosciences price targets, generally landing around the high US$170s. Updated models reflect slightly more conservative revenue growth assumptions and a marginally higher discount rate, partly offset by steady margin expectations and supportive views on Crenessity and Ingrezza.
Narrativ-Update • Jan 24

NBIX: Future Revenue Will Depend On Execution Across Two Key Franchises

Analysts have raised their fair value estimate for Neurocrine Biosciences to about US$204 from US$192. This reflects updated assumptions that include slightly stronger revenue growth, higher profit margins and a lower future P/E multiple after recent Street research refined expectations for Ingrezza, Crenessity and competitor dynamics.
Narrativ-Update • Jan 10

NBIX: Commercial Execution And Pipeline Progress Will Drive Future Shareholder Returns

Analysts have raised their fair value estimate for Neurocrine Biosciences from about $177.92 to $179.66, reflecting updated models that incorporate recent price target revisions, current product performance, and expectations regarding future competition and commercial execution. Analyst Commentary Recent research updates show a mix of optimism and caution around Neurocrine Biosciences, with most price target moves clustering around the high $160s to mid $180s and reflecting updated models on current products, competitive developments in congenital adrenal hyperplasia, and spending to support commercial execution.
Narrativ-Update • Dec 17

NBIX: Advancing CNS Pipeline Readouts Will Drive Future Shareholder Returns

Analysts have modestly increased their average price target for Neurocrine Biosciences by about $3, to roughly $178, citing stronger than expected product performance, sustained Ingrezza growth momentum, and growing confidence in the company’s advancing pipeline despite potential IRA related pricing headwinds. Analyst Commentary Street research remains broadly constructive on Neurocrine, with multiple firms nudging price targets higher as they factor in stronger execution, commercial visibility for Ingrezza and Crenessity, and a maturing late stage pipeline.
Narrativ-Update • Dec 03

NBIX: Late-Stage CNS Pipeline Readouts Will Drive Future Shareholder Value

Analysts have nudged their blended price target for Neurocrine Biosciences modestly higher to the high $170s to low $180s range, reflecting stronger than expected Ingrezza and Crenessity performance, confidence in commercial execution ahead of IRA related headwinds, and growing optimism around the longer term pipeline. Analyst Commentary Bullish analysts largely frame the recent pullback as a mismatch between robust fundamentals and short term market sentiment, with multiple firms lifting price targets into the mid $160s to mid $190s range even as shares consolidated.
Narrativ-Update • Nov 19

NBIX: Late-Stage Pipeline Advancements Will Drive Shareholder Value Amid Industry Headwinds

Neurocrine Biosciences' analyst price target has increased modestly, up by $3 to $174. Analysts cite ongoing strong commercial performance, expanded sales force initiatives, and a robust late-stage pipeline as supporting factors for sustained growth potential.
Narrativ-Update • Nov 05

NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value

The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.
Narrativ-Update • Oct 22

Analysts Boost Neurocrine Biosciences Price Target Citing Strong Revenue Outlook and Clinical Results

Analysts have raised their price target for Neurocrine Biosciences from $168.25 to $169.95. They cite stronger revenue outlooks for key products and supportive recent clinical trial data as the main reasons for this adjustment.

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:NBIX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20285,0131,4191,8001,86417
12/31/20274,4731,0941,3781,42420
12/31/20263,77453090969321
3/31/20263,102669831864N/A
12/31/20252,861479749783N/A
9/30/20252,683428593637N/A
6/30/20252,510348529567N/A
3/31/20252,413306492530N/A
12/31/20242,355341557595N/A
9/30/20242,243386440476N/A
6/30/20242,120339495530N/A
3/31/20241,982370614645N/A
12/31/20231,887250362390N/A
9/30/20231,784191385409N/A
6/30/20231,673176281296N/A
3/31/20231,59964237255N/A
12/31/20221,489155323339N/A
9/30/20221,38958177201N/A
6/30/20221,29712133164N/A
3/31/20221,20871102129N/A
12/31/20211,13490233257N/A
9/30/20211,069445328347N/A
6/30/20211,032365251265N/A
3/31/20211,045402266280N/A
12/31/20201,046407218229N/A
9/30/20201,04293222232N/A
6/30/20201,006205337350N/A
3/31/2020887177283295N/A
12/31/201978837N/A147N/A
9/30/201967521N/A100N/A
6/30/201960518N/A71N/A
3/31/2019519-39N/A27N/A
12/31/201845121N/A101N/A
9/30/201841410N/A91N/A
6/30/2018323-52N/A13N/A
3/31/2018233-106N/A-55N/A
12/31/2017162-143N/A-94N/A
9/30/201767-194N/A-167N/A
6/30/20176-220N/A-188N/A
3/31/2017N/A-200N/A-154N/A
12/31/201615-141N/A-106N/A
9/30/201615-126N/A-90N/A
6/30/201615-123N/A-77N/A
3/31/201615-107N/A-49N/A
12/31/201520-89N/A-38N/A
9/30/201520-79N/A-38N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NBIXDas prognostizierte Gewinnwachstum (24.2% pro Jahr) liegt über der Sparquote (3.5%).

Ertrag vs. Markt: NBIXDie Erträge des Unternehmens (24.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (18.1% pro Jahr).

Hohe Wachstumserträge: NBIXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: NBIXDie Einnahmen des Unternehmens (12% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (12.8% pro Jahr).

Hohe Wachstumseinnahmen: NBIXDie Einnahmen des Unternehmens (12% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NBIXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (20.9%)

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/07/08 15:58
Aktienkurs zum Tagesende2026/07/08 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Neurocrine Biosciences, Inc. wird von 39 Analysten beobachtet. 21 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Martha FreitagArgus Research Company
Brian SkorneyBaird
Aydin HuseynovBenchmark Company